BioCryst Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 86   

Articles published

BCRX 11.16 +0.07 (0.68%)
price chart
Stock Update: BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX)
[GLOBE NEWSWIRE] BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) (TREND ANALYSIS) announced financial results for the third quarter ended September 30, 2014.
BioCryst Pharmaceuticals Inc. (BCRX) Has Broken Out Of Today's Range
BioCryst Pharmaceuticals Inc. (BCRX) Has Broken Out Of Today's Range. By RTT News, October 14, 2014, 10:12:00 AM EDT. A A A. Vote up.
Related articles »  
Stock Update: BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)
[GLOBE NEWSWIRE] BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) announced financial results for the third quarter ended September 30, 2014.
Dyax Corp. (DYAX), BioCryst Pharmaceuticals, Inc. (BCRX), Achillion ...  StockWise Daily
BioCryst Pharmaceuticals Trading Down 4.7% After Analyst Downgrade (BCRX)  WKRB News
Related articles »  
Why BioCryst Pharmaceuticals Inc. Shares Soared
What: Shares of BioCryst Pharmaceuticals (NASDAQ: BCRX ) , a biotechnology company focused on developing small-molecule drugs designed to block enzymes which are vital to the disease development process, spiked higher by as much as 22% after ...
BioCryst Crushes It on Rare Immune Disorder Drug Trial  24/7 Wall St.
BioCryst Announces Positive Results From OPuS-1, a Phase 2 Trial of BCX4161 ...  MarketWatch
Related articles »  
Stock Update: BioCryst Pharmaceuticals Inc. (NASDAQ:BCRX) to Present at ...
Taking a look at the company's recent performance, BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) reported Third quarter earnings for fiscal 2014 on November 06th.
High Short Interest Alert:Biocryst Pharmaceuticals , Avanir Pharmaceuticals Inc  Markets Insider
Worth Watching Stocks - BioCryst Pharmaceuticals, Inc.(NASDAQ:BCRX ...  Techsonian (press release)
Related articles »  
Can BioCryst Pharmaceuticals, Inc. (BCRX) Stop The Ebola Outbreak?
Currently there are no approved vaccines or drugs to treat Ebola. All doctors can do is give patients fluid and try to stop the bleeding that Ebola causes.
Biocryst Pharmaceuticals (BCRX) Highlighted As Today's Perilous Reversal ...
BioCryst Pharmaceuticals' (BCRX) CEO Jon Stonehouse on Q2 2014 Results ...  Seeking Alpha (registration)
Related articles »  
BioCryst Pharmaceuticals (BCRX) Reports Ahead Of Street For Q3
Today, drug maker BioCryst Pharmaceuticals, Inc. (BCRX) posted quarterly results for the three-month period ended September 30.
BioCryst Reports Third Quarter 2014 Financial Results  GlobeNewswire (press release)
Related articles »  
BioCryst Pharma Inc (BCRX) Coverage Initiated By JP Morgan With Overweight
BioCryst Pharmaceuticals, Inc. (BCRX) was initiated with a 'Overweight' and it was given a $20.00 price target at JP Morgan (JPM) in a research report issued to clients on Friday.
UPDATE: JPMorgan Starts BioCryst Pharma (BCRX) at Overweight (subscription)
Related articles »  
BioCryst to Launch NHP Ebola Drug Safety, Efficacy Studies 'Within Weeks'
BioCryst Pharmaceuticals, Inc. announced this morning that their small-molecule, nucleoside analogue, BCX-4430, would be entering a dose ranging efficacy study in non-human primates within the next few weeks.
Hope For Ebola Cure  Bidness ETC
BioCryst expects to begin Ebola study in weeks  Yahoo News
Related articles »  
Ebola Stock Short Interest Surprise
Allied Healthcare Products Inc. (NASDAQ: AHPI) saw its short interest increase to 50,000 from its previous reading of 6,000 shares, with one day to cover in mid-October.